Loading organizations...
§ Private Profile · Bottmingen, Switzerland
Clinical-stage biopharmaceutical company developing precision biologics for immuno-oncology, autoimmune, and inflammatory diseases.
Anaveon is a clinical-stage biopharmaceutical company developing precision biologics to modulate cytokines and reprogram the immune system, based in Basel, Switzerland. The enterprise focuses on engineered antibodies and selective interleukin-2 (IL-2) agonists, such as its lead clinical assets ANV419 and ANV600, which are designed to safely stimulate the body's immune response to fight solid tumors and inflammatory disorders. Operating with approximately 24 employees, the biotechnology firm advances its proprietary immunotherapies through Phase I and Phase II clinical trials to address areas of high unmet medical need. To support its ongoing research and development pipeline, Anaveon has raised CHF 110 million in Series B financing backed by a syndicate of prominent life sciences investors, including Syncona, Forbion, Novartis Venture Fund, and Pfizer Ventures. The organization was founded in 2017 by industry scientists Andreas Katopodis and Onur Boyman.
Anaveon has raised $155.0M across 2 funding rounds.
Anaveon has raised $155.0M in total across 2 funding rounds.
Anaveon has raised $155.0M in total across 2 funding rounds.
Anaveon's investors include Forbion, High-Tech Gründerfonds, Kurma Partners, Therese Liechtenstein, Novartis Venture Fund, Omega Funds, Pfizer Venture Investments, Pontifax Venture Capital, Seroba Life Sciences, Vincent Brichard, Tim Anderson, Novartis.
Anaveon has raised $155.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $120M Series B | Forbion | High Tech Gründerfonds, Kurma Partners, Therese Liechtenstein, Novartis Venture Fund, Omega Funds, Pfizer Venture Investments, Pontifax Venture Capital, Seroba Life Sciences, Vincent Brichard, TIM Anderson, Novartis, Martin Murphy | Announced |
| Feb 1, 2019 | $35M Series A | Dominic Schmidt | Novartis Venture Fund, Florian Müllershausen | Announced |
Anaveon is a clinical-stage biopharmaceutical company developing novel immunotherapies that harness the immune system to treat cancers and immune-mediated diseases with high unmet needs.[1][2][4] Its lead products include ANV-419 (IL-2R agonist for metastatic melanoma, Phase 2) and ANV-600 (IL-2Rβγ x PD-1 bispecific for advanced solid tumors, Phase 2), targeting effector T-cell enhancement to boost anti-tumor responses.[2][5][6] Founded in 2017 and headquartered in Basel, Switzerland, Anaveon has raised over 146 million CHF from high-profile investors, employing a team of immunology, protein engineering, and clinical experts to advance its pipeline from discovery through Phase 2 trials.[1][3][6]
The company serves oncology patients and those with inflammatory/autoimmune conditions, solving the problem of immune system dysfunction by selectively activating T-cells while minimizing toxicity, as seen in ongoing trials and preclinical data presentations.[1][2][5]
Anaveon was founded on December 11, 2017, by Onur Boyman and Andreas Katopodis, scientists and industry experts with deep roots in immunology and immuno-oncology.[1][2] Emerging from breakthroughs in harnessing cytokines like IL-2 and IL-21 to amplify immune responses against tumors, the company started with a focus on protein-engineered therapies to improve safety and efficacy over traditional treatments.[1][5] Early traction came from securing over 146 million CHF in funding, enabling rapid progression to clinical stages, with pivotal moments including Phase 1/2 initiations for ANV-419 (2023) and ANV-600 combinations with PD-1 inhibitors.[2][3][6]
Anaveon rides the bispecific antibody and cytokine engineering wave in immuno-oncology, where market forces favor next-gen IL-2/IL-21 therapies amid PD-1 resistance in solid tumors.[2][5][6] Timing aligns with surging demand for precision immunotherapies—global oncology market projected to grow amid ~20 million annual cancer cases—positioning Anaveon to influence the ecosystem through collaborations and data readouts that validate T-cell selective agonists.[2][6] By addressing immune exhaustion in advanced cancers and autoimmunity, it contributes to the shift from monotherapy to combo regimens, amplifying impact in Switzerland's biotech hub and global trials.[1][4]
Anaveon is poised for Phase 2 readouts in 2025-2026 on ANV-419 and ANV-600, potentially unlocking partnerships or approvals in melanoma/solid tumors, with ANV-700 advancing to IND.[2][6] Trends like AI-driven protein design and multi-specific combos will accelerate its pipeline, while board enhancements signal M&A readiness in a consolidating biotech sector. As it transforms immune insights into therapies, Anaveon's selective T-cell focus could redefine treatments for unmet needs, building on its 2017 vision of immune-powered cures.[1][5]